



## Vir Biotechnology to Present at 40th Annual Cowen Healthcare Conference

February 25, 2020

SAN FRANCISCO, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on immune approaches to treating and preventing serious infectious diseases, today announced that George Scangos, Ph.D., Chief Executive Officer will present at the 40<sup>th</sup> Annual Cowen Healthcare Conference on Tuesday, March 3<sup>rd</sup> at 11:20 a.m. ET.

A live webcast of the presentation can be accessed under Events & Presentations in the Investors section of the Vir website at [www.vir.bio](http://www.vir.bio) and will be archived there following the presentation for 30 days.

### About Vir Biotechnology

Vir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of five product candidates targeting hepatitis B virus, influenza A, human immunodeficiency virus and tuberculosis. For more information, please visit [www.vir.bio](http://www.vir.bio).

### Contact:

Vir Biotechnology, Inc.

### Investors

Neera Ravindran, MD

Head of Investor Relations & Strategic Communications

[nravindran@vir.bio](mailto:nravindran@vir.bio)

+1-415-506-5256

### Media

Lindy Devereux

Scient PR

[lindy@scientpr.com](mailto:lindy@scientpr.com)

+1-646-515-5730



Source: Vir Biotechnology, Inc.